Navigation Links
King and Pain Therapeutics Announce REMOXY(R) NDA Update
Date:7/7/2009

s and acquisitions, of novel branded prescription pharmaceutical products that complement the Company's focus in specialty-driven markets, particularly neuroscience, hospital care. King's wholly-owned subsidiary, Alpharma, Inc., is also a leader in the development, registration, manufacturing and marketing of pharmaceutical products for food producing animals.

About Pain Therapeutics, Inc.

Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel drugs. In addition to REMOXY, the Company has three drug candidates in clinical programs, including a novel radio-labeled monoclonal antibody to treat metastatic melanoma, as well as PTI-202 and PTI-721. Pain Therapeutics is also working on a new treatment for patients with hemophilia. For more information, please visit www.paintrials.com.

Forward Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Pain Therapeutics, Inc. and King Pharmaceuticals, Inc. disclaim any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the resubmission of the NDA for REMOXY(R), and the timing and content of any such resubmission; the need to generate stability data or any other information in connection with the resubmission; the Companies' plans to develop and commercialize REMOXY(R); the Companies' plans to work with the FDA in connection with the Complete Response Letter; and the potential approval of the NDA for REMOXY(R). Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements in
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes
2. Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
3. Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
4. PTC Therapeutics Receives $2.6 Million in Government Grants
5. Cell Therapeutics on Preliminary List of Additions to Russell 3000(R) Index and Russell Global(R) Index
6. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
7. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
8. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
9. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
10. Tobira Therapeutics Inc. Announces Key Addition to Scientific Advisory Board
11. PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. today ... pain has reached an important milestone, as Virobay has ... - a selective cathepsin S inhibitor.   ... double-blind, randomized, placebo-controlled study designed to evaluate the safety, ... in healthy adults. "The initiation of this ...
(Date:5/23/2013)... FL (PRWEB) May 23, 2013 On ... made trips to supermarkets to search for the growing ... store aisles. Results from a year long study were ... level in foods, specifically meats, over previous years. For ... how the growth of antibiotic resistant bacteria in food, ...
(Date:5/23/2013)... May 23, 2013 Northwest Biotherapeutics (NASDAQ: ... DCVax ® personalized immune therapies for solid tumor ... at this year,s American Society Of Clinical Oncology (ASCO) ... its leadership role in immune therapy.  (Logo: ... meeting is the pre-eminent conference focused on clinical treatment ...
(Date:5/23/2013)... May 23, 2013 Pressure BioSciences, Inc. (OTCQB: ... Company will host a teleconference to discuss its First ... update. The teleconference information is provided below: ... Daylight Time (EDT) Dial-in: (800) 875-3456 (U.S.); ... (Int,l) Passcode: VS22823 For those unable to ...
Breaking Biology Technology:Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2
... , , , , ... , Specific technique considerations , , ... , First, verify that both ,of your DNA constructs ... (for example, 1 g of DNA and 3 l FuGENE 6 Reagent) that ,provides good ...
... , , , , ... Observe Cytotoxicity (greater than 5 - ,10 % Cell Death) , , ... nontoxic to most cell ,types. If you observe more than 5 - 10 % cell ... ,table below for possible causes. , , ...
... , , Agencourt offers a single pass sequencing service , ... by our high performance sequencing pipeline, which processes over 20 million , ... , , Long Phred20 ... Rapid sample turnaround , GLP-compliant ...
Cached Biology Technology:Uses and Applications of FuGENE 6 Transfection Reagent 2Uses and Applications of FuGENE 6 Transfection Reagent 2Uses and Applications of FuGENE 6 Transfection Reagent 3SINGLE PASS SEQUENCING 2
(Date:5/23/2013)... overall health, development, and academic success of children, ... that all students have opportunities to engage in ... or moderate-intensity physical activity, says a new report ... suggest that only about half of school-age children ... and development. The report recommends that most ...
(Date:5/23/2013)... the world are billions of animal and plant specimens ... grasses, all stacked, stored and preserved in jars and ... be critical to understanding how the Earth,s biodiversity is ... if only the information were easily accessible. , ... help of a team from the University of Colorado ...
(Date:5/22/2013)... NEW YORK CITY, May 22, 2013 U.S. Forest ... multi-disciplinary team that, with funding from the TKF Foundation, ... spaces help communities and individuals recover from tragedy. , ... is one of six projects selected for grant funding. ... spaces and sacred spaces in recovery and resiliency, the ...
Breaking Biology News(10 mins):Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4'Landscapes of Resilience' to study how people use nature as a source of recovery 2
... This press release is available in Spanish . ... up with a way to detect pathogenic Escherichia coli and ... method. Similar methods have been developed to detect pathogenic ... the scientists with USDA,s Agricultural Research Service (ARS) represents a ...
... Medical Society ("Medical News & Perspectives", Jan. 19, ... Adamovich, a biomedical engineer. Adamovich and his research partners, ... PhD, PT, at the University of Medicine and Dentistry ... reality-based video game therapies to help stroke patients regain ...
... making engineers look twice at their ability to exhibit the ... These parasites will actually stick together like Cheerios swimming in ... to capillary force." This observation has made Virginia Tech engineers ... Their work appears in the journal, Soft Matter ...
Cached Biology News:Detecting pathogens in waterways: An improved approach 2JAMA features NJIT biomedical engineer helping stroke patients 2JAMA features NJIT biomedical engineer helping stroke patients 3When worms stick together and swim on thin water, what happens and why does it matter? 2
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... First-Strand cDNA Labeling System - dCTP ... reactions. For the generation and purification ... are packaged together for complete cDNA ... can be used for performing labeling ...
... Dye Pack, 12 x Cy5. The ... for microarray labeling.Higher reactivity Cy3 and ... per vial, at > 75% reactive ... and packed in foil packs for ...
... CyScribe GFX Purification Kit, 24 reactions. ... Cy3- and Cy5-labeled cDNA.Optimized reagents are ... and purification.Flexible and optimized protocols can ... with either Cy3- or Cy5-labeled nucleotides.Reliable ...
Biology Products: